Skip to main content
    V

    Viking Therapeutics Inc (VKTX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $25.47
    -1.18 (-4.43%)

    Market Cap: $3.39B

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    54%(21/39)
    Avg Surprise
    -1.51%
    Streak
    1 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-1.06
    Range$-1.38 - $-0.66
    16 analysts
    EPS Revisions
    1
    0
    7d
    9
    6
    30d
    EPS Estimate DriftChange to current
    90d ago$-1.10+3.2%
    60d ago$-1.08+1.1%
    30d ago$-1.07+0.1%
    7d ago$-1.07+0.1%
    Current$-1.06
    Revenue Consensus
    $0
    Range$0 - $0
    17 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-1.42
    Range$-2.17 - $-0.63
    16 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    17 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-1.42---
    Sep 26EST
    		-$-1.06---
    Jun 26
    Reported Jul 29
    		$-1.10$-1.21+9.09%Beat-89.7%
    Mar 26
    Reported Apr 29
    		$-1.37$-0.91-50.55%Miss-234.1%
    Dec 25
    Reported Feb 11
    		$-1.38$-0.90-53.33%Miss-331.2%
    Sep 25
    Reported Oct 22
    		$-0.81$-0.67-20.90%Miss-268.2%
    Jun 25
    Reported Jul 23
    		$-0.58$-0.44-31.82%Miss-190.0%
    Mar 25
    Reported Apr 23
    		$-0.41$-0.31-32.26%Miss-57.7%
    Dec 24
    Reported Feb 5
    		$-0.32$-0.27-18.52%Miss-28.0%
    Sep 24
    Reported Oct 23
    		$-0.22$-0.24+8.33%Beat+4.3%
    Jun 24
    Reported Jul 24
    		$-0.20$-0.27+25.93%Beat-5.3%
    Mar 24
    Reported Apr 24
    		$-0.26$-0.28+7.14%Beat-4.0%
    Dec 23
    Reported Feb 7
    		$-0.25$-0.25+0.00%Beat+3.8%
    Sep 23
    Reported Oct 25
    		$-0.23$-0.22-4.55%Miss-9.5%
    Jun 23
    Reported Jul 26
    		$-0.19$-0.20+5.00%Beat+17.4%
    Mar 23
    Reported Apr 26
    		$-0.25$-0.24-4.17%Miss-19.0%
    Dec 22
    Reported Feb 8
    		$-0.26$-0.23-13.04%Miss-62.5%
    Sep 22
    Reported Oct 26
    		$-0.21$-0.23+8.70%Beat-23.5%
    Jun 22
    Reported Jul 27
    		$-0.23$-0.21-9.52%Miss-15.0%
    Mar 22
    Reported Apr 27
    		$-0.21$-0.19-10.53%Miss-10.5%
    Dec 21
    Reported Feb 9
    		$-0.16$-0.19+15.79%Beat-6.7%
    Sep 21
    Reported Nov 3
    		$-0.17$-0.21+19.05%Beat-30.8%
    Jun 21
    Reported Jul 28
    		$-0.20$-0.20+0.00%Beat-53.8%
    Mar 21
    Reported Apr 28
    		$-0.19$-0.17-11.76%Miss-46.2%
    Dec 20
    Reported Feb 17
    		$-0.15$-0.15+0.00%Beat-50.0%
    Sep 20
    Reported Oct 28
    		$-0.13$-0.15+13.33%Beat-62.5%
    Jun 20
    Reported Jul 29
    		$-0.13$-0.14+7.14%Beat-18.2%
    Mar 20
    Reported Apr 30
    		$-0.13$-0.12-8.33%Miss-85.7%
    Dec 19
    Reported Feb 26
    		$-0.10$-0.13+23.08%Beat-42.9%
    Sep 19
    Reported Nov 5
    		$-0.08$-0.12+33.33%Beat+27.3%
    Jun 19
    Reported Aug 1
    		$-0.11$-0.09-22.22%Miss+15.4%
    Mar 19
    Reported May 2
    		$-0.07$-0.09+22.22%Beat+12.5%
    Dec 18
    Reported Mar 13
    		$-0.07$-0.10+30.00%Beat+50.0%
    Sep 18
    Reported Nov 7
    		$-0.11$-0.11+0.00%Beat+50.0%
    Jun 18
    Reported Aug 9
    		$-0.13$-0.12-8.33%Miss+38.1%
    Mar 18
    Reported May 9
    		$-0.08$-0.12+33.33%Beat+65.2%
    Dec 17
    Reported Mar 7
    		$-0.14$-0.17+17.65%Beat+22.2%
    Sep 17
    Reported Nov 8
    		$-0.22$-0.20-10.00%Miss-
    Jun 17
    Reported Aug 9
    		$-0.21$-0.19-10.53%Miss-
    Mar 17
    Reported May 10
    		$-0.23$-0.18-27.78%Miss-
    Dec 16
    Reported Mar 21
    		$-0.18$-0.20+10.00%Beat-

    Key Metrics

    Valuation
    P/E Ratio-5.47EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-88.80%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio4.72xQuick Ratio4.72x
    Trading Statistics
    Beta0.65Avg Volume9.02M
    52-Week High$43.1552-Week Low$25.28

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$28.34
    SMA 20$31.20
    SMA 50$32.46
    SMA 200$32.85
    EMA 10$28.44
    EMA 20$30.04
    EMA 50$31.88
    EMA 200$32.64

    MACD

    Line: -1.76Signal: -1.17Hist: -0.59

    ADX

    ADX: 15.5+DI: 20.3-DI: 32.5

    Aroon & PSAR

    Aroon Up40.0
    Aroon Down100.0
    PSAR$32.83

    Bollinger Bands

    Upper Band$40.02
    Lower Band$22.39
    %B Position5650%(Upper)
    Band Width0.17

    RSI (14-Day)

    Neutral
    33.6

    Momentum Oscillators

    Stoch %K3.3
    Stoch %D5.4
    Williams %R-98.6
    ROC (10d)-21.9%
    Momentum-7.13
    CCI (20d)-110.4
    MFI (14d)30.8

    Volatility Measures

    ATR (14d)$2.05(8.1%)
    StdDev (20d)4.41
    Hist Vol147.5%(High)

    Volume Flow

    VWAP$25.88
    OBV-6.7M
    AD Line-12.2M
    CMF (20d)0.010

    Volume Metrics

    Avg Vol (20d)9.6M
    Vol Ratio0.7x
    VWMA (20d)$34.44

    Pivot Points

    R3$29.30
    R2$28.75
    R1$27.70
    Pivot Point$27.15
    S1$26.10
    S2$25.55
    S3$24.50

    Advanced Oscillators

    TSI-18.75
    Ultimate Osc30.3
    KST-116.94

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$0$0$0$0$436,000$0
    Cost of Revenue$0$0$94,000$0$0$0$110,000$0$0$0$74,000$0
    Gross Profit$0$0$-94,000$0$0$0$-110,000$0$0$0$-74,000$0
    Operating Expenses$132.60M$164.13M$164.75M$98.56M$74.60M$55.49M$46.29M$36.56M$34.07M$34.10M$29.34M$27.27M
    R&D$115.75M$150.15M$153.46M$89.95M$60.15M$41.39M$30.99M$22.79M$23.77M$24.10M$20.50M$18.38M
    SG&A$16.84M$13.97M$11.28M$8.61M$14.42M$14.08M$15.25M$13.77M$10.29M$9.97M$8.78M$8.89M
    Operating Income$-132,597,000$-164,125,000$-164,738,000$-98,561,000$-74,574,000$-55,469,000$-46,238,000$-36,556,000$-34,054,000$-34,073,000$-29,285,000$-27,265,000
    Interest Income$4.54M$5.80M$7.04M$7.77M$9.03M$9.86M$10.84M$11.53M$11.82M$6.75M$4.71M$4.73M
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-128,022,000$-158,325,000$-157,650,000$-90,787,000$-65,537,000$-45,605,000$-35,367,000$-24,940,000$-22,234,000$-27,328,000$-24,547,000$-22,532,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-128,022,000$-158,325,000$-157,662,000$-90,787,000$-65,561,000$-45,629,000$-35,417,000$-24,940,000$-22,250,000$-27,356,000$-24,605,000$-22,534,000
    EBITDA$-133,295,000$-165,333,000$-166,375,000$-100,466,000$-76,825,000$-58,467,000$-50,135,000$-41,339,000$-39,397,000$-36,792,000$-31,855,000$-30,335,000
    EBIT$-132,567,000$-164,125,000$-164,738,000$-98,559,000$-74,570,000$-55,469,000$-46,238,000$-36,471,000$-34,054,000$-34,073,000$-29,253,000$-27,265,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about VKTX

    News

    VKTX Initiated Coverage by UBS -- Rating Set to Buy with Price T

    UBS has initiated coverage on Viking Therapeutics (VKTX) with a Buy rating and a price target of $94.00, suggesting significant upside from its current trading price of $27.37. Despite this positive outlook...

    GuruFocus•10/15/26•Somewhat-Bullish

    UBS Initiates Viking Therapeutics at Buy With $94 Price Target

    UBS has initiated coverage on Viking Therapeutics with a "Buy" rating and a price target of $94. This positive outlook suggests confidence in the company's future performance and potential for significant stock...

    Moomoo•10/15/26•Bullish

    Viking starts oral Phase 3 program for Viking Therapeutics stock

    Viking Therapeutics has initiated its SUNRISE Phase 3 program for oral VK2735, with two studies enrolling 560 adults each to test a daily tablet for obesity and obesity with type 2 diabetes. The trials aim to evaluate...

    ad-hoc-news.de•10/15/26•Bullish

    Viking Therapeutics stock hits 52-week low at 25.77 USD

    Viking Therapeutics Inc. stock has hit a 52-week low of $25.77, marking a 26.52% decline over the past year. Despite this, InvestingPro data suggests the stock might be undervalued with a fair value of $27.46...

    Investing.com•10/14/26•Neutral

    Viking Therapeutics Announces Initiation of VK2735 Oral Phase 3 Clinical Program in Patients with Obesity

    Viking Therapeutics has initiated its SUNRISE Phase 3 clinical program for oral VK2735, a dual GLP-1/GIP agonist, to treat obesity in adults with and without type 2 diabetes. The program includes two 68-week studies...

    PR Newswire•10/14/26•Bullish

    VKTX Valuation and Fair Value

    P/E
    -5.5x
    PEG
    -0.0x
    P/B
    7.3x
    See GNG's fair value

    VKTX Profitability: Margins, ROIC and FCF

    Operating margin
    0.0%
    Net margin
    0.0%
    ROE
    -88.8%

    VKTX Competitors

    CompanyTicker
    Cidara Therapeutics IncCDTX
    CareDx IncCDNA
    Pulse Biosciences IncPLSE
    Tarsus Pharmaceuticals IncTARS
    Legend Biotech CorpLEGN
    Xenon Pharmaceuticals IncXENE
    Veracyte IncVCYT
    Arcutis Biotherapeutics IncARQT

    Sector: Healthcare

    VKTX Analyst Ratings

    Consensus
    Buy
    Analysts
    20
    Strong Buy
    5
    Buy
    13
    Hold
    2
    Sell
    0
    Strong Sell
    0

    VKTX Bull Case vs Bear Case

    Bull case

    • 90.0% of VKTX's analyst ratings are Buy or Strong Buy.

    Bear case

    • VKTX beat EPS estimates in 25.0% of its last 8 reported quarters.

    VKTX Earnings: Beat Rate and Next Report

    Beat rate
    2 of 8 quarters (25.0%)
    Average surprise
    -23.7%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-1.06
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    9 up, 6 down

    Frequently Asked Questions About VKTX

    Does VKTX pay dividends?

    Viking Therapeutics Inc (VKTX) does not currently pay a regular dividend.

    What is VKTX's market cap?

    Viking Therapeutics Inc (VKTX) has a market capitalization of $3.39B with a current stock price of $25.47.

    Related stocks

    Sector: Healthcare

    All stocks starting with V

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In